Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants

Pediatric Blood and Cancer

Volumn 46, Issue 7, 2006, Pages 745-754

  Mahller, Yonatan Y ^a   Rangwala, Fatima ^a   Ratner, Nancy ^a   Cripe, Timothy P ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Neurofibromatosis type 1 (NF1); Oncolytic herpes simplex virus; Protein kinase R; Ras

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; GUANOSINE TRIPHOSPHATE; INITIATION FACTOR 2; NEUROFIBROMIN; ONCOLYTIC VIRUS; PROTEIN KINASE R; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; VIRUS VECTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE MUTATION; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFECTION SENSITIVITY; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHWANN CELL; TUMOR CELL LINE; VERO CELL; VIRUS MUTANT; VIRUS REPLICATION;

APOPTOSIS; CELL LINE, TUMOR; EIF-2 KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 1, HUMAN; HUMANS; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; ONCOLYTIC VIROTHERAPY; PROTO-ONCOGENE PROTEINS P21(RAS); SCHWANN CELLS; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 33646586994     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20565     Document Type: Article

References (46)

1. Huson SM, Compston DA, Clark R et al. A genetic study of von Recklinghausen neurofibromatosis in south east wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26:704-711.
2. Peltonen J, Jaakkola S, Lebwohl M, et al. Cellular differentiation and expression of matrix genes in type I neurofibromatosis. Lab Invest 1988;59:760-771.
3. Sheela S, Riccardi VM, Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 1990;111:645-653.
4. Carroll SL, Stonecypher MS. Tumor suppressor mutation and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: The role of dysregulated growth factor signaling. J Neuropathol Exp Neurol 2005;64:1-9.
5. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in South-East Wales. Brain 1988;111:1355-1381.
6. Zoller ME. Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125-2131.
7. Evans DGR, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis-1. J Med Genet 2002;39:311-314.
8. Sorensen SA, Mulvihill JJ, Nielsen A. Long term follow up of von Recklinhausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986;314:1010-1015.
9. Takeuchi A, Ushigome S. Diverse differentiation in malignant peripheral nerve sheath tumors associated with neurofibromatosis-1: An immunohistochemical and ultrastructural study. Histopathology 2001;39:298-309.
10. Angelov L, Salhia B, Roncari L, et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 1999;59:5536-5541.
11. Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis 1. J Child Neurol 2002;17:578-584.
12. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type-1 neurofibromatosis patients. Nature 1992;356:713-715.
13. Guha A, Lau N, Huvar I, et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996;12:507-513.
14. ras contributes to malignant tumor growth in von Recklinghausen (type-1) neurofibromatosis. Cell 1992;69:265-273.
15. Topal O, Yilmaz T, Ogretmenoglu O. Giant malignant peripheral nerve sheath tumor of the neck in a patient with neurofibromatosis-1. Int J Pediatr Otorhinolaryngol 2004;68:1465-1467.
16. Neville H, Corpron C, Blakely ML, et al. Pediatric neurofibrosarcoma. J Pediatr Surg 2003;38:343-346.
17. Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997;79:1438-1446.
18. Mahgoub N, Taylor BR, Gratiot M, et al. Myeloid malignancies induced by alkylating agents in NF1 mice. Blood 1999;93:3617-3623.
19. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004;11:643-664.
20. Marken JM, Parker JN, Gillespie GY, et al. Genetically engineered human herpes simplex virus in the treatment of brain tumors. Herpes 2001;8:17-22.
21. Liu RB, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 2005;12:647-654.
22. Nakamori M, Fu X, Pettaway CA, et al. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004;60:53-60.
23. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-1334.
24. Parikh NS, Currier MA, Mahller YY. et al. Oncolytic herpes simplex virus mutants are more efficacous than wild-type adenovirus type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005;44:469-478.
25. Currier MA, Adams LC, Mahller YY, et al. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 2005;12:407-416.
26. Liu RB, Rabkin SD. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J (Engl.) 2005;118:307-312.
27. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant. G207 for the treatment of malignant glioma: Results of a phase 1 trial. Gene Ther 2000;7:867-874.
28. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357:525-526.
29. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication competent herpes simplex Oncolytic virus for the treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2002;21:8a.
30. Farassati F, Yang AD, Lee PW. Oncogenes in the Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3:745-750.
31. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 1988;166:41-51.
32. Gale M, Katze MG. Molecular mechanisms of interferon mediated by viral directed inhibition of PKR, the interferon induced protein kinase. Pharmacol Ther 1998;78:29-46.
33. Mossman KL, Smiley JR. Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon induced barriers to virus replication. J Virol 2002;76:1995-1998.
34. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double stranded RNA-activated protein kinase. Proc Natl Acad Sci 1997;94:843-848.
35. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of HSV g34.5 gene mediated virulence toward tumor and cycling cells. J Viol 1999;73:7556-7564.
36. Kambara H, Okano H, Chiocca EA, et al. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65:2832-2839.
37. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
38. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
39. Rosenbaum T, Rosenbaum C, Winner U, et al. Long term culture and characterization of human neurofibroma derived Schwann cells. J Neurosci Res 2000;61:524-532.
40. Declue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Inv 2000;105:1233-1241.
41. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the nfl:p53 mouse tumor model. Cancer Res 2002;62:4507-4513.
42. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005;7:65-75.
43. Cerrito MG, Galbaugh T, Wang W, et al. Dominant negative Ras enhances lactogenic hormone induced differentiation by blocking activation of the Ral-Mek-Erk signal transduction pathway. J Cell Physiol 2004;201:244-258.
44. Goodkin ML, Morton ER, Blaho JA. Herpes simplex virus infection and apoptosis. Int Rev Immunol 2004;23:141-172.
45. Stanziale SF, Petrowsky H, Adusumilli PS, et al. Infection with Oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity. Clin Cancer Res 2004;10:3225-3232.
46. Mashour GA, Moulding HG, Chahlavi A, et al. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol 2001;169:64-71.